A fellow eye controlled study of HUCNS-SC sub-retinal transplantation in subjects with bilateral GA AMD. All subjects will be assigned to HUCNS-SC transplantation.
Full Title of Study: “A Phase II Proof-of-Concept Study of the Safety and Efficacy of HUCNS-SC Subretinal Transplantation in Subjects With Geographic Atrophy of Age-Related Macular Degeneration”
- Study Type: Interventional
- Study Design
- Allocation: N/A
- Intervention Model: Single Group Assignment
- Primary Purpose: Treatment
- Masking: None (Open Label)
- Study Primary Completion Date: May 2016
A fellow eye controlled study of HUCNS-SC sub-retinal transplantation in subjects with bilateral geographic atrophy (GA) age-related macular degeneration (AMD). All subjects will be assigned to HUCNS-SC transplantation. All subjects will be followed for efficacy and safety for 12 months. An independent data monitoring committee (IDMC) will review adverse events for the duration of the study.
- Biological: HuCNS-SC sub-retinal transplantation
- HuCNS-SC sub-retinal transplantation in subjects with bilateral GA AMD
Arms, Groups and Cohorts
- Experimental: HuCNS-SC
- HuCNS-SC sub-retinal transplantation
Clinical Trial Outcome Measures
- GA area based on fundus autofluorescence
- Time Frame: 12 months
Participating in This Clinical Trial
- GA associated with AMD in both eyes. Total area of GA determined by fundus autofluorescence.
- BCVA of 20/320 or better in each eye at screening assessment
- Prior or concurrent choroidal neovascularization in either eye by clinical exam and/or fluorescein angiography as determined by the investigator or the reading center.
- Retinal or macular disease of any other cause in either eye.
- Diagnosis of glaucoma in either eye.
- Uncontrolled intraocular pressure in either eye
- Compromised renal function defined as eGFR <60mL/min and urine protein-to-creatinine ration >0.3 is spot urine collection.
- History of or active autoimmune disease.
- Previous organ, tissue or bone marrow transplantation.
- Seropositive for HIV, hepatitis B or C, or CMV IgM
Gender Eligibility: All
Minimum Age: 50 Years
Maximum Age: 90 Years
Are Healthy Volunteers Accepted: No
- Lead Sponsor
- StemCells, Inc.
- Provider of Information About this Clinical Study
- Overall Official(s)
- Joel Naor, MD, Study Chair, StemCells, Inc.
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.